Xspray Pharma publishes its Year-end Report, January – December 2018

”Following determined efforts, we demonstrated performance in 2018 that has brought us significantly closer to a market launch of HyNap-Dasa and have thus increased Xspray’s possibilities of building shareholder value.” Per Andersson, CEO Xspray Pharma AB (publ) Fourth quarter, October – December 2018, parent company Amounts in brackets refer to the corresponding period for the […]